Dr Andrew Kassianos

Honorary Senior Fellow

Royal Brisbane Clinical Unit
Faculty of Medicine

Overview

Dr Kassianos is a Senior Scientist at the Conjoint Internal Medical Laboratory, Queensland Health. Dr Kassianos has made significant contributions to understanding the cell-cell communication between discrete kidney cell and immune cell populations and the therapeutic potential of targeting this cross-talk in chronic kidney disease (CKD). Dr Kassianos has been integral in the development of innovative tools for CKD analytics: (i) in situ/ex vivo profiling for integrating CKD molecular profiles with histopathology; and (ii) preclinical models for screening novel CKD therapeutics. His research is internationally recognised in the field of CKD pathobiology.

Dr Kassianos has contributed to the fields of nephrology and immunology with 41 publications, >2000 career citations (~48 citations/paper) and invited international keynote lectures. Dr Kassianos has a continued record of success in attracting competitive research funding (>$2M as CI), including an NHMRC Dora Lush Scholarship (2007-2010), an RBWH Foundation Fellowship (2012-2014) and two NHMRC Project Grants as CIA (2016-2019; 2019-2022). Dr Kassianos has publications in high-ranking specialist (nephrology, immunology) and generalist journals, including five editorial commentaries in publication issues. These include 21 publications (~50% of his papers) as first or senior author/co-author – of which, 19 (90%) are in top field-weighted journals (Q1, top 10%), including Kidney Int, J Am Soc Nephrol, Cell Death Dis and J Extracell Vesicles. During this time, Dr Kassianos has supervised 5 Early Career Researchers, 5 PhD students (3 to completion) and 2 Masters students (both to completion). Dr Kassianos is also an Editor at Frontiers in Physiology and has contributed to 3 NHMRC grant review panels (2019-2021).

Qualifications

  • Doctor of Philosophy, The University of Queensland

Publications

View all Publications

Supervision

View all Supervision

Available Projects

  • Principal Advisor: Dr Andrew Kassianos

    Email: Andrew.Kassianos@health.qld.gov.au

    Organisational unit: QIMR Berghofer and Royal Brisbane Clinical Unit

    Chronic kidney disease (CKD) is a worldwide public health burden, defined as decreased kidney function for >3months. In Australia alone, 1 in 3 adults (6 million people) are at risk of developing CKD, with the annual financial cost of CKD >$5 billion. Furthermore, there is no cure for CKD. Understanding the pathological mechanisms of CKD progression will fast-track the development of urgently needed clinical therapeutics.

    Our team have established specialised epithelial cells of the kidney proximal tubule (PTEC) as central players in CKD. Under the pathological conditions of CKD, we show that human PTEC:

    1. Undergo primary cell death;
    2. Release small extracellular vesicles (exosomes) from their (polarised) apical membrane that directly induce secondary cell death in adjacent healthy PTEC; and
    3. Produce danger signals (including exosomes) from their (polarised) basolateral membrane that activate local immune cells and indirectly induce secondary cell death in adjacent PTEC.

    This project will explore the therapeutic potential of targeting these ‘wave of death’ check-points in established pre-clinical human models of CKD. Outcomes of this proposal will have a major health impact in providing the rationale for innovative, evidence-based therapies for CKD. A PhD scholarship is available for this project.

View all Available Projects

Publications

Book Chapter

  • Raghubar, Arti M., Crawford, Joanna, Jones, Kahli, Lam, Pui Y., Andersen, Stacey B., Matigian, Nicholas A., Ng, Monica S Y, Healy, Helen, Kassianos, Andrew J. and Mallett, Andrew J. (2023). Spatial transcriptomics in kidney tissue. Kidney research: experimental protocols. (pp. 233-282) edited by Tim D. Hewitson, Nigel D. Toussaint and Edward R. Smith. New York, NY USA: Humana New York. doi: 10.1007/978-1-0716-3179-9_17

  • Kassianos, Andrew J., Jongbloed, Sarah L., Hart, Derek N.J. and Radford, Kristen J. (2010). Isolation of Human Blood DC Subtypes. Dendritic cell protocols. (pp. 45-54) edited by Shalin H. Naik. New York, NY United States: Humana Press. doi: 10.1007/978-1-60761-421-0_3

Journal Article

Conference Publication

  • Kassianos, Andrew J., Giuliani, Kurt, Nag, Purba, Hong, Seokchan, Wang, Xiangju, Johnston, Rebecca L., Adams, Benjamin, Grivei, Anca, Ho, Kenneth, Ng, Monica, Waddell, Nicola, Forbes, Josephine M., Healy, Helen and Kassianos, Andrew J. (2023). Hypoxia and interleukin (IL)-1β synergistically induce cellular senescence in human proximal tubular epithelial cells (PTEC). 58th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), Christchurch, New Zealand, 4-6 September 2023. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/nep.14216

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Doctor Philosophy — Associate Advisor

Possible Research Projects

Note for students: The possible research projects listed on this page may not be comprehensive or up to date. Always feel free to contact the staff for more information, and also with your own research ideas.

  • Principal Advisor: Dr Andrew Kassianos

    Email: Andrew.Kassianos@health.qld.gov.au

    Organisational unit: QIMR Berghofer and Royal Brisbane Clinical Unit

    Chronic kidney disease (CKD) is a worldwide public health burden, defined as decreased kidney function for >3months. In Australia alone, 1 in 3 adults (6 million people) are at risk of developing CKD, with the annual financial cost of CKD >$5 billion. Furthermore, there is no cure for CKD. Understanding the pathological mechanisms of CKD progression will fast-track the development of urgently needed clinical therapeutics.

    Our team have established specialised epithelial cells of the kidney proximal tubule (PTEC) as central players in CKD. Under the pathological conditions of CKD, we show that human PTEC:

    1. Undergo primary cell death;
    2. Release small extracellular vesicles (exosomes) from their (polarised) apical membrane that directly induce secondary cell death in adjacent healthy PTEC; and
    3. Produce danger signals (including exosomes) from their (polarised) basolateral membrane that activate local immune cells and indirectly induce secondary cell death in adjacent PTEC.

    This project will explore the therapeutic potential of targeting these ‘wave of death’ check-points in established pre-clinical human models of CKD. Outcomes of this proposal will have a major health impact in providing the rationale for innovative, evidence-based therapies for CKD. A PhD scholarship is available for this project.